Monkeypox treatment with tecovirimat in the Central African Republic under an Expanded Access Programme

Festus Mbrenga, Emmanuel Nakouné, Christian Malaka, Josephine Bourner, Jake Dunning, Guy Vernet, Peter Horby, Piero Olliaro
doi: https://doi.org/10.1101/2022.08.24.22279177

Article Information

doi 
https://doi.org/10.1101/2022.08.24.22279177
History 
  • August 26, 2022.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Author Information

  1. Festus Mbrenga1,
  2. Emmanuel Nakouné1,
  3. Christian Malaka1,
  4. Josephine Bourner2,*,
  5. Jake Dunning2,
  6. Guy Vernet1,
  7. Peter Horby2 and
  8. Piero Olliaro2
  1. 1Institut Pasteur de Bangui, Bangui, Central African Republic
  2. 2Pandemic Sciences Institute, University of Oxford, Oxford, OX3 7DQ, United Kingdom
  1. ↵*Corresponding author:
    Josephine Bourner, josephine.bourner{at}ndm.ox.ac.uk
Back to top
Posted August 26, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Monkeypox treatment with tecovirimat in the Central African Republic under an Expanded Access Programme
Festus Mbrenga, Emmanuel Nakouné, Christian Malaka, Josephine Bourner, Jake Dunning, Guy Vernet, Peter Horby, Piero Olliaro
medRxiv 2022.08.24.22279177; doi: https://doi.org/10.1101/2022.08.24.22279177
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area